VITASPRING BIOMEDICAL CO. LTD.
VSBC · OTCMCIK 1697884fmd_0NG5A932XN3BPK9M2EDFM8TYVYServices · Services-Commercial Physical & Biological ResearchTemplate: Standard
Coverage: Feb 01, 2016 to Jul 31, 2026, 39 periods
Latest annual · FY2026
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (0)
- Net income
- (0)
Latest quarter · Q2 FY2027
Millions- Total revenues
- 0
- Operating income
- (0)
- Net income
- (0)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2023 to FY2026
- n/m
- Revenue, 5 yearsFY2021 to FY2026
- n/m
- Net income, 5 yearsFY2021 to FY2026
- n/m
VITASPRING BIOMEDICAL CO. LTD. (VSBC) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2026 | FY2025 | Change | Source |
|---|---|---|---|---|
| Revenue | $0 | $0 | 10-K 2026-06-17 · proof | |
| Gross profit | $0 | $0 | 10-K 2026-06-17 · proof | |
| Operating income | -$385,411 | -$679,914 | 10-K 2026-06-17 · proof | |
| Net income | -$415,368 | -$774,922 | 10-K 2026-06-17 · proof | |
| Cash from operating activities | -$2,688 | -$14,675 | 10-K 2026-06-17 · proof | |
| Total assets | $14,676 | $14,378 | +2.1% | 10-Q 2026-06-17 · proof |
| Total liabilities | $4.4 million | $4 million | +10.3% | 10-Q 2026-06-17 · proof |
| Cash and cash equivalents | $2,084 | $0 | 10-Q 2026-06-17 · proof |
- What was VITASPRING BIOMEDICAL CO. LTD. (VSBC)'s revenue in fiscal 2026?
- VITASPRING BIOMEDICAL CO. LTD. (VSBC) reported revenue of $0 for fiscal 2026 (the year ended Jan 31, 2026), against $0 the year before. Source: the 10-K filed with the SEC on Jun 17, 2026. SEC
- What was VITASPRING BIOMEDICAL CO. LTD. (VSBC)'s gross profit in fiscal 2026?
- VITASPRING BIOMEDICAL CO. LTD. (VSBC) reported gross profit of $0 for fiscal 2026 (the year ended Jan 31, 2026), against $0 the year before. Source: the 10-K filed with the SEC on Jun 17, 2026. SEC
- What was VITASPRING BIOMEDICAL CO. LTD. (VSBC)'s operating income in fiscal 2026?
- VITASPRING BIOMEDICAL CO. LTD. (VSBC) reported operating income of -$385,411 for fiscal 2026 (the year ended Jan 31, 2026), against -$679,914 the year before. Source: the 10-K filed with the SEC on Jun 17, 2026. SEC
- What was VITASPRING BIOMEDICAL CO. LTD. (VSBC)'s net income in fiscal 2026?
- VITASPRING BIOMEDICAL CO. LTD. (VSBC) reported net income of -$415,368 for fiscal 2026 (the year ended Jan 31, 2026), against -$774,922 the year before. Source: the 10-K filed with the SEC on Jun 17, 2026. SEC
- What was VITASPRING BIOMEDICAL CO. LTD. (VSBC)'s cash from operating activities in fiscal 2026?
- VITASPRING BIOMEDICAL CO. LTD. (VSBC) reported cash from operating activities of -$2,688 for fiscal 2026 (the year ended Jan 31, 2026), against -$14,675 the year before. Source: the 10-K filed with the SEC on Jun 17, 2026. SEC
- What are VITASPRING BIOMEDICAL CO. LTD. (VSBC)'s total assets?
- As of Jan 31, 2026, VITASPRING BIOMEDICAL CO. LTD. (VSBC) reported total assets of $14,676, against $14,378 a year earlier (+2.1%). Source: the 10-Q filed with the SEC on Jun 17, 2026. SEC
- What are VITASPRING BIOMEDICAL CO. LTD. (VSBC)'s total liabilities?
- As of Jan 31, 2026, VITASPRING BIOMEDICAL CO. LTD. (VSBC) reported total liabilities of $4.4 million, against $4 million a year earlier (+10.3%). Source: the 10-Q filed with the SEC on Jun 17, 2026. SEC
- What are VITASPRING BIOMEDICAL CO. LTD. (VSBC)'s cash and cash equivalents?
- As of Jan 31, 2026, VITASPRING BIOMEDICAL CO. LTD. (VSBC) reported cash and cash equivalents of $2,084, against $0 a year earlier. Source: the 10-Q filed with the SEC on Jun 17, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:VSBC&period_type=annual&limit=5"Information only, not investment advice.